0      0


VD02 - The Evolving Landscape of Frontline Therapy in Chronic Lymphocytic Leukemia


‐ Nov 10, 2023 10:15am

Disclosures:

Amber Koehler has participated in advisory boards for AbbVie, Janssen, and AstraZeneca.
Josie Montegaard has participated in advisory boards for AbbVie and Beigene.


Learning Objectives:

  • List currently recommended agents for frontline therapy in chronic lymphocytic leukemia (CLL)
  • Outline key patient characteristics that may help in choice of frontline therapy for treatment-naive CLL
  • Consider patient and lifestyle factors when selecting a treatment course
  • Develop a management plan for common adverse events that may occur in patients with CLL on frontline therapy